Index RUT P/E - EPS (ttm) -1.05 Insider Own 41.28% Shs Outstand 56.47M Perf Week -3.30%
Market Cap 248.56M Forward P/E - EPS next Y -1.25 Insider Trans 0.12% Shs Float 33.17M Perf Month 18.92%
Income -58.67M PEG - EPS next Q -0.23 Inst Own 42.92% Short Float 9.00% Perf Quarter 66.04%
Sales 0.00M P/S - EPS this Y 19.89% Inst Trans 3.11% Short Ratio 9.76 Perf Half Y 100.00%
Book/sh 4.77 P/B 0.92 EPS next Y -31.47% ROA -19.44% Short Interest 2.99M Perf Year -36.96%
Cash/sh 4.79 P/C 0.92 EPS next 5Y - ROE -20.15% 52W Range 1.94 - 8.31 Perf YTD 66.04%
Dividend Est. - P/FCF - EPS past 5Y -138.68% ROI -21.59% 52W High -47.05% Beta 1.93
Dividend TTM - Quick Ratio 38.61 Sales past 5Y 0.00% Gross Margin - 52W Low 126.80% ATR (14) 0.28
Dividend Ex-Date - Current Ratio 38.61 EPS Y/Y TTM 15.82% Oper. Margin 0.00% RSI (14) 60.23 Volatility 4.22% 7.03%
Employees 124 Debt/Eq 0.01 Sales Y/Y TTM - Profit Margin - Recom 2.33 Target Price 6.67
Option/Short Yes / Yes LT Debt/Eq 0.01 EPS Q/Q 43.03% Payout - Rel Volume 0.36 Prev Close 4.41
Sales Surprise - EPS Surprise 24.04% Sales Q/Q - Earnings May 08 AMC Avg Volume 305.98K Price 4.40
SMA20 7.58% SMA50 19.11% SMA200 50.69% Trades
Volume 110,213 Change -0.23%
Date
Action
Analyst
Rating Change
Price Target Change
May-07-24 Upgrade Piper Sandler
Neutral → Overweight
$6 → $12
Nov-14-23 Downgrade Piper Sandler
Overweight → Neutral
$42 → $6
Aug-15-23 Downgrade Wedbush
Outperform → Neutral
$19 → $6
Aug-15-23 Downgrade SVB Securities
Outperform → Market Perform
$6
Aug-15-23 Downgrade RBC Capital Mkts
Outperform → Sector Perform
$23 → $7
May-04-23 Upgrade Goldman
Sell → Neutral
$6
Jun-10-22 Initiated Wedbush
Outperform
$21
May-02-22 Initiated RBC Capital Mkts
Outperform
$30
Jan-19-22 Initiated Goldman
Sell
$10
Apr-20-21 Initiated SVB Leerink
Outperform
$36
Apr-20-21 Initiated Piper Sandler
Overweight
$42
Apr-20-21 Initiated Goldman
Neutral
$28
Show Previous Ratings
May-10-24 03:36PM
May-08-24 11:55PM
04:05PM
May-07-24 07:12AM
06:30AM
10:31AM
Loading…
Mar-20-24 10:31AM
06:58AM
(Thomson Reuters StreetEvents)
Mar-19-24 08:53PM
05:33PM
04:01PM
Mar-12-24 06:30AM
Dec-18-23 12:00PM
Nov-14-23 07:28PM
Nov-13-23 04:05PM
Aug-15-23 03:02PM
09:59AM
Loading…
09:59AM
02:34AM
Aug-14-23 04:05PM
04:01PM
Jun-18-23 08:03AM
May-31-23 06:30AM
May-09-23 04:05PM
May-08-23 06:05AM
Apr-24-23 06:30AM
Apr-11-23 09:55AM
Apr-04-23 02:47PM
Mar-14-23 04:05PM
Mar-09-23 06:33AM
Feb-08-23 06:30AM
Dec-21-22 06:46AM
05:15AM
Loading…
Dec-14-22 05:15AM
Dec-07-22 04:01PM
Nov-28-22 10:37AM
Nov-03-22 04:05PM
Oct-17-22 04:05PM
Sep-22-22 06:30AM
Aug-08-22 04:05PM
Aug-03-22 06:30AM
Jun-21-22 09:57AM
Jun-01-22 06:30AM
May-09-22 04:05PM
Mar-30-22 06:30AM
Mar-23-22 02:53PM
Mar-10-22 04:02PM
Mar-09-22 06:30AM
Feb-28-22 04:05PM
Feb-10-22 06:30AM
Feb-01-22 04:05PM
Jan-19-22 12:51PM
Dec-23-21 05:00AM
Nov-09-21 04:05PM
Sep-24-21 07:55AM
Sep-08-21 06:30AM
Sep-03-21 07:33AM
Aug-09-21 04:05PM
Jun-26-21 04:30AM
Jun-07-21 04:10PM
04:05PM
May-10-21 04:05PM
Mar-30-21 04:05PM
Mar-25-21 11:56PM
Design Therapeutics, Inc. operates as a biotechnology company that develops therapies for serious degenerative disorders. It is created to design, develop and commercialize a novel class of small molecule therapeutic candidates (GeneTACs) designed to directly address the underlying basis of genetic disease. The company was founded by Pratik Shah and Aseem Z. Ansari on December 18, 2017 and is headquartered in Carlsbad, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Schmid John P. Director Mar 25 '24 Buy 3.74 17,809 66,606 26,965 Mar 25 07:10 PM Berger Heather A. Director Mar 25 '24 Buy 3.74 1,300 4,866 1,300 Mar 25 07:09 PM Schmid John P. Director Mar 22 '24 Buy 3.62 9,156 33,133 9,156 Mar 25 07:10 PM LAPPE RODNEY W Director Sep 29 '23 Buy 2.35 21,000 49,287 133,024 Oct 02 06:01 PM William Arsani Director Aug 29 '23 Buy 2.44 1,960,000 4,782,400 3,000,000 Aug 30 06:02 PM Prasad Deepa Director Aug 29 '23 Buy 2.31 12,000 27,670 23,806 Aug 30 06:06 PM William Arsani Director Aug 28 '23 Buy 2.15 275,000 591,250 1,040,000 Aug 30 06:02 PM
Index RUT P/E - EPS (ttm) -0.46 Insider Own 6.58% Shs Outstand 148.26M Perf Week 8.47%
Market Cap 303.93M Forward P/E - EPS next Y -0.17 Insider Trans 0.50% Shs Float 138.50M Perf Month 17.82%
Income -64.40M PEG - EPS next Q -0.10 Inst Own 38.76% Short Float 6.96% Perf Quarter -35.13%
Sales 171.36M P/S 1.77 EPS this Y 16.67% Inst Trans -3.02% Short Ratio 5.44 Perf Half Y 30.57%
Book/sh -0.06 P/B - EPS next Y 53.78% ROA -19.58% Short Interest 9.64M Perf Year -27.05%
Cash/sh 0.59 P/C 3.48 EPS next 5Y - ROE -617.16% 52W Range 1.46 - 3.26 Perf YTD -12.77%
Dividend Est. - P/FCF - EPS past 5Y 38.13% ROI -25.27% 52W High -37.12% Beta 1.78
Dividend TTM - Quick Ratio 1.81 Sales past 5Y 195.35% Gross Margin 76.58% 52W Low 40.41% ATR (14) 0.12
Dividend Ex-Date - Current Ratio 2.37 EPS Y/Y TTM 18.68% Oper. Margin -26.25% RSI (14) 59.85 Volatility 6.91% 6.35%
Employees 377 Debt/Eq - Sales Y/Y TTM 41.18% Profit Margin -37.58% Recom 1.00 Target Price 4.58
Option/Short Yes / Yes LT Debt/Eq - EPS Q/Q -10.02% Payout - Rel Volume 0.44 Prev Close 1.98
Sales Surprise -3.71% EPS Surprise -32.08% Sales Q/Q 22.42% Earnings May 09 BMO Avg Volume 1.77M Price 2.05
SMA20 11.40% SMA50 4.00% SMA200 -4.46% Trades
Volume 778,734 Change 3.54%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-28-24 Initiated Oppenheimer
Outperform
$5
Aug-28-23 Initiated Craig Hallum
Buy
$4.50
Oct-21-22 Initiated Jefferies
Buy
$4
Apr-28-22 Initiated Craig Hallum
Buy
$6.50
Nov-17-21 Initiated SVB Leerink
Outperform
$6
Oct-29-21 Initiated H.C. Wainwright
Buy
$4
Apr-07-21 Resumed RBC Capital Mkts
Outperform
$11
Feb-18-20 Initiated Piper Sandler
Overweight
$12
Jul-16-18 Initiated RBC Capital Mkts
Outperform
$24
Jul-16-18 Initiated Leerink Partners
Outperform
$24
Jul-16-18 Initiated Jefferies
Buy
$23
Show Previous Ratings
May-10-24 03:21PM
12:36PM
12:27AM
(Thomson Reuters StreetEvents)
May-09-24 11:55AM
08:10AM
07:11AM
Loading…
07:11AM
(Associated Press Finance)
07:00AM
May-06-24 07:42AM
07:00AM
May-02-24 07:00AM
Apr-03-24 04:05PM
Apr-02-24 07:00AM
Mar-07-24 01:47PM
11:56AM
Mar-06-24 11:16PM
(Thomson Reuters StreetEvents) -19.48%
12:52PM
Loading…
12:52PM
08:15AM
07:17AM
(Associated Press Finance)
07:02AM
07:00AM
Mar-05-24 09:42AM
Feb-28-24 07:00AM
Feb-05-24 07:00AM
Jan-11-24 08:30AM
Jan-10-24 08:00AM
Jan-08-24 02:48PM
Jan-05-24 04:05PM
Jan-04-24 07:00AM
Dec-27-23 07:00AM
Dec-23-23 07:32PM
02:00PM
Loading…
Dec-20-23 02:00PM
Nov-17-23 01:07PM
Nov-10-23 04:00PM
01:53AM
(Thomson Reuters StreetEvents)
Nov-09-23 11:30AM
08:10AM
07:17AM
(Associated Press Finance)
07:00AM
Oct-26-23 06:15PM
Oct-16-23 07:00AM
Sep-27-23 08:00AM
Sep-20-23 07:36AM
Sep-14-23 04:05PM
Aug-28-23 07:00AM
Aug-17-23 11:00AM
Aug-11-23 09:09AM
Aug-10-23 11:59AM
Aug-08-23 12:05PM
09:15AM
07:13AM
07:00AM
Aug-01-23 07:00AM
Jul-31-23 07:00AM
Jun-29-23 04:19PM
Jun-22-23 01:50PM
Jun-21-23 07:00AM
Jun-19-23 12:58PM
Jun-01-23 07:00AM
May-09-23 11:33PM
(Thomson Reuters StreetEvents) +13.75%
07:25AM
07:00AM
May-08-23 06:37AM
May-02-23 07:00AM
Apr-18-23 07:00AM
Apr-17-23 06:25AM
Apr-06-23 08:21AM
Apr-05-23 01:18PM
Mar-30-23 07:00AM
Mar-29-23 04:05PM
Mar-08-23 11:52PM
(Thomson Reuters StreetEvents) -11.76%
06:00AM
Feb-23-23 07:00AM
Feb-02-23 07:00AM
Jan-30-23 07:00AM
Jan-05-23 04:03PM
07:00AM
Dec-31-22 09:33AM
Dec-15-22 07:00AM
Nov-24-22 10:56AM
Nov-23-22 06:00AM
Nov-16-22 09:53AM
Nov-09-22 07:00AM
Nov-02-22 10:01AM
07:00AM
Nov-01-22 07:00AM
Oct-20-22 10:28AM
06:00AM
Oct-06-22 06:07AM
Sep-05-22 12:00PM
Aug-10-22 07:00AM
Aug-03-22 07:30AM
Aug-01-22 07:30AM
Jul-24-22 10:03AM
Jun-09-22 07:09AM
(Simply Wall St.) -10.00%
May-27-22 09:38AM
May-12-22 04:02PM
May-11-22 07:00AM
May-04-22 08:00AM
Mar-23-22 10:34AM
Mar-16-22 07:00AM
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Schmid John P. Director May 10 '24 Buy 1.91 5,400 10,314 16,400 May 10 04:04 PM JOHNSON JOHN Director Mar 18 '24 Option Exercise 1.99 215,600 429,044 751,412 Mar 18 05:32 PM Schmid John P. Director Mar 14 '24 Buy 2.16 4,500 9,720 11,000 Mar 14 09:03 PM SHERMAN JEFFREY W Director Nov 27 '23 Buy 1.87 5,400 10,098 5,400 Nov 29 04:09 PM Pieper Steven See Remarks Nov 20 '23 Buy 1.95 28,000 54,600 1,176,912 Nov 21 04:16 PM HALKUFF DAWN Director Nov 20 '23 Buy 1.84 5,410 9,954 5,410 Nov 21 04:20 PM Shannon John Patrick Jr See Remarks Nov 17 '23 Buy 1.64 30,769 50,400 1,408,575 Nov 17 05:58 PM Schmid John P. Director Nov 16 '23 Buy 1.51 6,500 9,815 6,500 Nov 17 06:35 PM PERSKY MARLA Director Nov 14 '23 Buy 1.58 6,370 10,058 6,370 Nov 15 04:13 PM Edick Paul R See Remarks Aug 09 '23 Buy 2.38 10,000 23,794 2,288,064 Aug 09 06:57 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
